The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome ACS 2-thrombolysis in myocardial Infarction 51)

Journal of the American College of Cardiology

Volumn 62, Issue 9, 2013, Pages 777-781

  Krantz, Mori J ^a,b,c   Kaul, Sanjay ^d,e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b DENVER HEALTH MEDICAL CENTER   (United States)

^c Colorado Prevention Center ^*  (United States)

^d CEDARS SINAI MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

acute coronary syndrome(s); antithrombotic therapy; informative censuring; missing data; rivaroxaban triple

Indexed keywords

ACETYLSALICYLIC ACID; APIXABAN; CLOPIDOGREL; DABIGATRAN; PLACEBO; RIVAROXABAN; VORAPAXAR;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; THROMBOSIS;

ACS; ACUTE CORONARY SYNDROME(S); CARDIOVASCULAR; CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE; CRDAC; CV; FDA; FOOD AND DRUG ADMINISTRATION; INFORMATIVE CENSURING; MACE; MAJOR ADVERSE CARDIAC EVENT(S); MI; MISSING DATA; MYOCARDIAL INFARCTION; RIVAROXABAN; TRIPLE ANTITHROMBOTIC THERAPY;

ACUTE CORONARY SYNDROME; ANTICOAGULANTS; CORONARY THROMBOSIS; DOUBLE-BLIND METHOD; FACTOR XA; HUMANS; MORPHOLINES; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REPRODUCIBILITY OF RESULTS; THIOPHENES; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84882796805     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.05.024     Document Type: Review

References (21)

1. V.L. Rooger, A.S. Go, and D.M. Lloyd-Jones Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2 Lancet 2 1988 349 360
3. H. Jneid, J.L. Anderson, and R.S. Wright 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST- elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 60 2012 645 681
4. M. Skeppholm, A. Kallner, K. Malmqvist, M. Blomback, and H. Wallen Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res 128 2011 483 489
5. U.S. Food and Drug Administration. May 23, 2012, Meeting of the Cardiovascular and Renal Drugs Advisory Committee. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/ucm285415.htm. Accessed November 13, 2012.
6. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Approval Package for Application Number 202439Orig1s000. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2011/202439Orig1s000Approv. pdf. Accessed November 13, 2012.
7. J.L. Mega, E. Braunwald, and S.D. Wiviott Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
8. J. Oldgren, A. Budaj, C. Granger for the RE-DEEM Investigators Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
9. J.H. Alexander, R.D. Lopes, and S. James Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
10. P. Tricoci, Z. Huang, and C. Held Thrombin-receptor antagonist vorapaxar in acute coronary syndromes N Engl J Med 366 2012 20 33
11. J. Oldgren, L. Wallentin, and J.H. Alexander New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis Eur Heart J 2013 Mar 6 [E-pub ahead of print]
12. U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for Industry-Providing Evidence of Effectiveness for Human Drug and Biological Products. Available at: http://www.fda.gov/downloads/ Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm078749.pdf. Accessed November 13, 2012.
13. K.F. Schulz, and D.A. Grimes Sample size slippages in randomised trials: exclusions and the lost and wayward Lancet 359 2002 781 785
14. S.V. Rao, K. O'Grady, and K.S. Pieper A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes J Am Coll Cardiol 47 2006 809 816
15. Marciniak TA, for the U.S. Food and Drug Administration. NDA 202-439: Rivaroxaban for Acute Coronary Syndromes. Available at: http://www.fda.gov/ downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/UCM305921.pdf. Accessed November 13, 2012.
16. National Research Council: The Panel on Handling Missing Data in Clinical Trials The Prevention and Treatment of Missing Data in Clinical Trials 2010 National Academies Press Washington, DC
17. R. Little The prevention and treatment of missing data in clinical trials New Engl J Med 367 2012 1355 1360
18. FDA again rejects ACS indication for rivaroxaban (Xarelto). Forbes. Available at: http://www.forbes.com/sites/larryhusten/2013/03/04/fda-again- rejects-acs-indication-for-rivaroxaban-xarelto/. Accessed March 21, 2013.
19. Rivaroxaban gets ACS indication recommendation from European regulators. theheart.org. Available at: http://www.theheart.org/article/1521155.do?utm- medium=email&utm-source=20130322-breaking&utm-campaign=newsletter. Accessed March 22, 2013.
20. U.S. Food and Drug Administration. February 3, 2009, Meeting of the Cardiovascular and Renal Drugs Q 4 Advisory Committee. Available at: http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ CardiovascularandRenalDrugsAdvisoryCommittee/ucm125999.htm. Accessed March 22, 2013
21. U.S. Food and Drug Administration. Ticagrelor NDA 22-433 Briefing Document for Cardiovascular and Renal Drugs Advisory Committee Meeting. Available at: http://www.fda.gov/downloads/AdvisoryCommitteesMeetingMaterials/ Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM220197.pdf. Accessed March 22, 2013.